Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

A surge in respiratory illness is typical for this time of year, and the simultaneous outbreak of highly contagious norovirus is piling on to the public health risk. Commonly known as stomach flu, ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Alone and in combination with other lower respiratory tract disease signs and symptoms, dyspnea is the best predictor of severe RSV outcomes.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...

COVID-19, influenza, respiratory syncytial virus (RSV), and norovirus — have spread nationwide in especially high numbers ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.